表紙:ポリメラーゼ連鎖反応(PCR)の世界市場:現状分析と予測(2022年~2028年)
市場調査レポート
商品コード
1241377

ポリメラーゼ連鎖反応(PCR)の世界市場:現状分析と予測(2022年~2028年)

Polymerase Chain Reaction (PCR) Market: Current Analysis and Forecast (2022-2028)

出版日: | 発行: UnivDatos Market Insights Pvt Ltd | ページ情報: 英文 155 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=151.55円
ポリメラーゼ連鎖反応(PCR)の世界市場:現状分析と予測(2022年~2028年)
出版日: 2023年02月01日
発行: UnivDatos Market Insights Pvt Ltd
ページ情報: 英文 155 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

世界のポリメラーゼ連鎖反応(PCR)の市場規模は、研究機関や法医学研究所におけるポリメラーゼ連鎖反応(PCR)の利用の増加により、約9%の安定した成長が見込まれています。

当レポートでは、世界のポリメラーゼ連鎖反応(PCR)市場について調査分析し、市場力学、動向と機会、企業プロファイルなどの情報を提供しています。

目次

第1章 市場のイントロダクション

第2章 調査手法・前提条件

第3章 市場の要約

第4章 エグゼクティブサマリー

第5章 ポリメラーゼ連鎖反応(PCR)市場に対するCOVID-19の影響

第6章 ポリメラーゼ連鎖反応(PCR)市場の収益(2020年~2028年)

第7章 市場の考察:タイプ別

  • リアルタイムRT-PCR
  • 従来のPCR
  • デジタルPCR
  • その他

第8章 市場の考察:用途別

  • 感染症
  • がん
  • 遺伝性疾患
  • その他

第9章 市場の考察:エンドユーザー別

  • 病院・診療所
  • 製薬・バイオテクノロジー産業
  • 学術・研究所
  • その他

第10章 市場の考察:地域別

  • 北米
    • 米国
    • カナダ
    • その他の北米
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他の欧州
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • その他のアジア太平洋
  • その他の地域

第11章 ポリメラーゼ連鎖反応(PCR)の市場力学

  • 市場促進要因
  • 市場の課題
  • 影響の分析

第12章 ポリメラーゼ連鎖反応(PCR)の市場機会

第13章 ポリメラーゼ連鎖反応(PCR)の市場動向

第14章 デマンドサイドとサプライサイドの分析

  • デマンドサイド分析
  • サプライサイド分析

第15章 バリューチェーン分析

第16章 価格分析

第17章 戦略的考察

第18章 競合シナリオ

  • 競合情勢
    • ポーターのファイブフォース分析

第19章 企業プロファイル

  • Thermo Fisher Scientific Inc.
  • Bio-Rad Laboratories Inc.
  • QIAGEN
  • Agilent Technologies Inc.
  • Standard Biotools
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co. Inc.
  • Abbott
  • Promega Corporation
  • Takara Bio Inc.

第20章 免責事項

目次
Product Code: UMME211694

Polymerase chain reaction (PCR) is a laboratory technique used to amplify DNA sequences. The polymerase chain reaction enables investigators to obtain the large quantities of DNA that are required for various experiments and procedures in molecular biology, forensic analysis, evolutionary biology, and medical diagnostics. The rise in demand for advanced diagnostics and growing application in clinical diagnostics is expected to increase the demand for polymerase reaction tests. For instance, in August 2022, GenScript USA launched a real-time polymerase chain reaction (RT-PCR) monkeypox test for research lab use. The kit is based on RT-PCR technology and PCR amplification in one-step.

The Polymerase Chain Reaction (PCR) Market is expected to grow at a steady rate of around 9% owing to the increasing application of polymerase chain reaction (PCR) in research and forensic laboratories. Major companies in the market growing focus on gene-based research and the launch of new and innovative technologies. For instance, in July 2021, PathStore, a France-based multinational company launched the COVID-19 RT-PCR test priced at ₹299 (USD 3.65), the lowest so far among the private sector diagnostic industry.

Based on type, the polymerase chain reaction market is segmented into real-time RT-PCR, conventional PCR, digital PCR, and others. The digital PCR segment is expected to grow with a significant CAGR during the forecast period. Digital PCR is widely used for molecular detection with accurate quantification. Moreover, advancements in digital PCR technology and rises in product launches propel the segment. For instance, in July 2021, Stilla Technologies launched an access program for the industry's first six-color digital PCR system. The new dPCR platform offers high multiplexing and sensitivity for advancing cancer & liquid biopsy studies, cell & gene therapies, infectious disease & COVID-19 research, and environmental testing.

Based on application, the polymerase chain reaction market is segmented into infectious diseases, cancer, inherited disorders, and others. The cancer segment held a significant market share in 2021. The rising prevalence of cancer is the significant factor responsible for the growth of the market as PCR techniques are used in various gene-based studies which provide physicians with more data about the causes of cancer and change the way some forms of the disease are treated. According to the American Cancer Society, in 2021, there will be an estimated 1.9 million new cancer cases diagnosed and 608,570 cancer deaths in the U.S..

Based on end-users, the market is fragmented into hospitals & clinics, pharmaceutical & biotechnology industries, academic & research labs, and others. Among these, hospitals & clinics are expected to grow with a significant CAGR during the forecast period. This is mainly due to the rising incidences of various infectious and chronic diseases coupled with the rapid incorporation of PCR techniques in clinical diagnostics globally. Also, the clinical applications of PCR technologies are vast and offer opportunities to improve healthcare across the breadth of medical specialties.

For a better understanding of the market adoption of the Polymerase chain reaction (PCR) industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. Europe is the second dominant region due to the increasing prevalence of cancer cases that require an accurate diagnosis. Furthermore, the increase in research and development activities for advancement in PCR technology and the rise in collaboration agreements among companies for development boosts the growth of the polymerase chain reaction market. For instance, in January 2022, Qiagen, a leading developer of diagnostic devices, entered into collaboration with Atila BioSystems and Actome GmbH to provide non-invasive prenatal testing (NIPT) solutions to QIAGEN's dPCR and licensing & co-marketing agreement.

Some of the major players operating in the market include: Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., QIAGEN, Agilent Technologies Inc., Standard Biotools, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Abbott, Promega Corporation, Takara Bio Inc.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

  • 1.1. Market Definitions
  • 1.2. Main Objective
  • 1.3. Stakeholders
  • 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

  • 2.1. Research Process of the Polymerase Chain Reaction Market
  • 2.2. Research Methodology of the Polymerase Chain Reaction Market
  • 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE POLYMERASE CHAIN REACTION MARKET

6 POLYMERASE CHAIN REACTION MARKET REVENUE (USD BN), 2020-2028F

7 MARKET INSIGHTS BY TYPE

  • 7.1. Real-Time RT-PCR
  • 7.2. Conventional PCR
  • 7.3. Digital PCR
  • 7.4. Others

8 MARKET INSIGHTS BY APPLICATION

  • 8.1. Infectious Diseases
  • 8.2. Cancer
  • 8.3. Inherited Disorders
  • 8.4. Others

9 MARKET INSIGHTS BY END USER

  • 9.1. Hospitals & Clinics
  • 9.2. Pharmaceutical & Biotechnology Industries
  • 9.3. Academic & Research Labs
  • 9.4. Others

10 MARKET INSIGHTS BY REGION

  • 10.1. North America
    • 10.1.1. The U.S.
    • 10.1.2. Canada
    • 10.1.3. Rest of North America
  • 10.2. Europe
    • 10.2.1. Germany
    • 10.2.2. The U.K.
    • 10.2.3. France
    • 10.2.4. Italy
    • 10.2.5. Spain
    • 10.2.6. Rest of Europe
  • 10.3. Asia-Pacific
    • 10.3.1. China
    • 10.3.2. Japan
    • 10.3.3. India
    • 10.3.4. Rest of Asia-Pacific
  • 10.4. Rest of World

11 POLYMERASE CHAIN REACTION MARKET DYNAMICS

  • 11.1. Market Drivers
  • 11.2. Market Challenges
  • 11.3. Impact Analysis

12 POLYMERASE CHAIN REACTION MARKET OPPORTUNITIES

13 POLYMERASE CHAIN REACTION MARKET TRENDS

14 DEMAND AND SUPPLY-SIDE ANALYSIS

  • 14.1. Demand Side Analysis
  • 14.2. Supply Side Analysis

15 VALUE CHAIN ANALYSIS

16 PRICING ANALYSIS

17 STRATEGIC INSIGHTS

18 COMPETITIVE SCENARIO

  • 18.1. Competitive Landscape
    • 18.1.1. Porters Fiver Forces Analysis

19 COMPANY PROFILED

  • 19.1. Thermo Fisher Scientific Inc.
  • 19.2. Bio-Rad Laboratories Inc.
  • 19.3. QIAGEN
  • 19.4. Agilent Technologies Inc.
  • 19.5. Standard Biotools
  • 19.6. F. Hoffmann-La Roche Ltd.
  • 19.7. Merck & Co. Inc.
  • 19.8. Abbott
  • 19.9. Promega Corporation
  • 19.10. Takara Bio Inc.

20 DISCLAIMER